Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Gauthreaux

Retina Specialist Lafayette, LA Medical Doctor

NPI 1710942065 CMS profile 611258

1101 S College Rd, Suite 304, Lafayette, LA 70503

Open in the dashboard

General payments

$6,548

246 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Gauthreaux of Lafayette, LA is reported in the CMS Open Payments database as having received $6,548 across 246 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,626 54
2024 General $1,220 45
2023 General $905 36
2022 General $920 36
2021 General $600 26
2020 General $485 17
2019 General $792 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Gauthreaux
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Scott Gauthreaux were reported at $1,626. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Scott Gauthreaux Retina Specialist median Middle half National median
2019 $792 $410 $157–$1,517 $163
2020 $485 $168 $65–$778 $114
2021 $600 $258 $101–$1,161 $132
2022 $920 $418 $162–$1,488 $149
2023 $905 $476 $178–$1,312 $160
2024 $1,220 $520 $188–$1,372 $164
2025 $1,626 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $1,602 57 payments
  2. Alimera Sciences, Inc. $898 47 payments
  3. EyePoint Pharmaceuticals US, Inc. $549 7 payments
  4. AbbVie, Inc. $499 22 payments
  5. Genentech USA, Inc. $452 24 payments
  6. Mallinckrodt Hospital Products Inc. $441 14 payments
  7. Apellis Pharmaceuticals, Inc. $427 17 payments
  8. ANI Pharmaceuticals, Inc. $369 12 payments
  9. Harrow Eye, LLC $331 6 payments
  10. Iridex Corporation $179 3 payments
  11. Other $800 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,242 242 payments
  2. Education $214 3 payments
  3. Entertainment $93 1 payment
Products named General payments · program years 2019–2025
  1. EYLEA $849 32 payments
  2. EYLEA HD $785 26 payments
  3. ILUVIEN Ophthalmology $718 36 payments
  4. OZURDEX $454 20 payments
  5. ACTHAR $441 14 payments
  6. Syfovre $427 17 payments
  7. DEXYCU $322 5 payments
  8. PURIFIED CORTROPHIN GEL $243 4 payments
  9. ILUVIEN treatment of diabetic macular edema in patients who have been previously treated with corticosteroid $240 15 payments
  10. Lucentis $236 10 payments
  11. Other $2,060 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

246 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record